Literature DB >> 10637199

Association of serology with the endovascular presence of Chlamydia pneumoniae and cytomegalovirus in coronary artery and vein graft disease.

C Bartels1, M Maass, G Bein, N Brill, J F Bechtel, R Leyh, H H Sievers.   

Abstract

BACKGROUND: Chemotherapeutic treatment for patients with symptomatic coronary artery disease to reduce cardiovascular events may be initiated in response to elevated antibody titers against Chlamydia pneumoniae or cytomegalovirus. How antibody titers are associated with the endovascular presence of these microorganisms is still unclear. METHODS AND
RESULTS: Antibody titers against C pneumoniae (microimmunofluorescence) and cytomegalovirus (ELISA) in patients undergoing primary (coronary desobliterates, n=80) or repeated CABG (occluded vein grafts, n=45) were correlated with the endovascular presence of the 2 microorganisms. C pneumoniae was detected by means of a nested polymerase chain reaction (PCR) and by culturing. Both conventional PCR and quantitative PCR were applied for detection of cytomegalovirus. C pneumoniae (PCR/culture) was detected in 19/9% (15/80 and 7/80) of coronary desobliterates and in 18/11% (8/45 and 5/45) of occluded vein grafts. There was no statistical evidence that IgG values differed between patients with or without C pneumoniae detection who were undergoing primary CABG. In contrast, repeated-CABG patients with a positive PCR (P=0.0027) or C pneumoniae culture (P=0.0018) had distinctly elevated IgG titers compared with patients in whom C pneumoniae was not detected. Cytomegalovirus could not be detected in the examined specimens.
CONCLUSIONS: Cytomegalovirus infection does not seem to be associated with advanced coronary artery lesions. C pneumoniae antibody titers are not associated with the endovascular presence of C pneumoniae in patients with coronary artery disease. The observed strong association between elevated IgG titers and the detection of C pneumoniae in occluded vein grafts warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10637199     DOI: 10.1161/01.cir.101.2.137

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

Review 1.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

Review 2.  Involvement of Chlamydia pneumoniae in atherosclerosis: more evidence for lack of evidence.

Authors:  Margareta M Ieven; Vicky Y Hoymans
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

3.  Chlamydia pneumoniae and Cardiovascular Disease.

Authors:  Maria Kolia; Ignatius William Fong
Journal:  Curr Infect Dis Rep       Date:  2002-02       Impact factor: 3.725

4.  Is the perceived association between Chlamydia pneumoniae and vascular diseases biased by methodology?

Authors:  Boulos Maraha; Hans Berg; Marjolein Kerver; Steef Kranendonk; Jaap Hamming; Jan Kluytmans; Marcel Peeters; Anneke van der Zee
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

Review 5.  Potential infectious etiologies of atherosclerosis: a multifactorial perspective.

Authors:  S O'Connor; C Taylor; L A Campbell; S Epstein; P Libby
Journal:  Emerg Infect Dis       Date:  2001 Sep-Oct       Impact factor: 6.883

6.  Chlamydia pneumoniae aggravates vein graft intimal hyperplasia in a rat model.

Authors:  Geoffrey T L Kloppenburg; Rick de Graaf; Gert E L M Grauls; Cathrien A Bruggeman; Frank R Stassen
Journal:  BMC Microbiol       Date:  2007-12-06       Impact factor: 3.605

7.  Association of circulating Chlamydia pneumoniae DNA with cardiovascular disease: a systematic review.

Authors:  Marek Smieja; James Mahony; Astrid Petrich; Jens Boman; Max Chernesky
Journal:  BMC Infect Dis       Date:  2002-10-01       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.